Get all premium features to the best stock analysis tool

Discloses “Going Concern” Explanatory Paragraph in Auditor's Report Discloses “Going Concern” Explanatory Paragraph in Auditor's Report

Initiative marks entry into Israel's rapidly growing autonomous AI defense, firefighting and first response activities Initiative marks entry into Israel's rapidly growing autonomous AI defense, firefighting and first response activities

CEO Letter to Stockholders highlights the Company's strategic and financial reset designed to strengthen BiomX in the near term and unlock future growth opportunities DOVER, Del., March 19, 2026 /PRNewswire/ -- BiomX Inc. (NYSE American: PHGE), today released the following letter from its Chief Executive Officer to stockholders.

Seasoned financial leaders join BiomX to support strategic execution and advancement of the company DOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer.

NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued a statement in response to recent unusual market activity in its common stock.

BiomX (PHGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Proceeds to Support the Company's Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic Alternatives Proceeds to Support the Company's Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic Alternatives